
Misonix, Inc. MSON
Misonix, Inc. Deferred Revenue 2011-2026 | MSON
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Misonix, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | 13.3 K | 27.9 K | 20.7 K | 40.9 K | 102 K | 146 K | 44.2 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 146 K | 13.3 K | 56.5 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
345 K | $ 2.21 | - | $ 3.45 M | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
59.8 M | $ 10.39 | -0.62 % | $ 1.4 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 12.99 | -0.46 % | $ 1.95 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 8.26 | -1.2 % | $ 593 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 9.56 | -14.34 % | $ 271 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 4.08 | -4.23 % | $ 864 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 70.52 | -1.02 % | $ 104 B | ||
|
Cytosorbents Corporation
CTSO
|
419 K | $ 0.66 | -2.96 % | $ 35.9 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 3.98 | -1.85 % | $ 148 M | ||
|
Establishment Labs Holdings
ESTA
|
1.21 M | $ 64.59 | -0.65 % | $ 1.91 B | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.43 | -0.11 % | $ 121 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 13.56 | -0.66 % | $ 876 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.5 | -2.44 % | $ 340 M | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 1.33 | - | $ 21.5 M | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 267.52 | -0.69 % | $ 7.55 B | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.07 | -4.84 % | $ 1.26 M | ||
|
AxoGen
AXGN
|
14 K | $ 31.67 | -3.3 % | $ 1.46 B | ||
|
Align Technology
ALGN
|
1.33 B | $ 170.8 | -3.02 % | $ 12.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 8.85 | -2.75 % | $ 682 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 33.42 | -0.95 % | $ 4.98 K | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.84 | 2.67 % | $ 158 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 0.38 | -2.91 % | $ 39.1 M | ||
|
IRadimed Corporation
IRMD
|
2.87 M | $ 102.83 | 0.03 % | $ 1.31 B |